Home > ISAAR > Past ISAARs

ISAAR 2013

13-15 March 2013
Kuala Lumpur Convention Centre, Kuala Lumpur, Malaysia

Plenary keynote lectures

Category Tentative Title Speaker Major Resistance Problems The US NIH/NIAID Antimicrobial Resistance Research Efforts: Opportunities for the Global Community Dennis Dixon The Impact of Emerging Diagnostic Techniques on Clinical Infectious Diseases Robert Moellering MERLE SANDE MEMORIAL LECTURE Resistance in gram-negatives; the saga renews David Livermore Treatment of Major Infections / Prevention of Resistance Developing novel antimicrobials: is there any hope? Karen Bush Transformative Proteomics in the Clinical Microbiology Laboratory: MALDI-TOF Mass Spectrometry Robin Patel Staphylococcus aureus: a model of microbial adaptation to antibiotics Keiichi Hiramatsu Strategies to Control Antimicrobial Resistance Future strategies to control antimicrobial resistance in Asia Jae-Hoon Song Global collaborations in tackling antimicrobial resistance Victor Lim How to fix the antibiotics pipeline? David Shlaes

DAY 1 : MAJOR RESISTANT PATHOGENS

Session Tentative Topic Speaker 13 March (Wednesday /09:00 - 11:00) Session 1 Pneumococcal resistance in the era of conjugate vaccines Evolution of serotypes, invasive diseases and resistance Ron Dagan Current epidemiology of pneumococcal resistance: is it worsening? So Hyun Kim Invasive pneumococcal disease and clinical implication of antimicrobial resistance in the conjugate vaccine era Cheng-Hsun Chiu Session 2 From MRSA to VRSA: a half-century evolution Clinical relevance of hVISA: is it a real threat? Benjamin Howden What do molecular epidemiological studies on CAMRSA tell us? Keryn Christiansen MIC Creep: Does it Exist? Ian Gould Session 3 Carbapenem resistance in gram negatives Carbapenem resistance in Enterobacteriaceae David Livermore Carbapenem resistance in non-fermenters Po-Ren Hsueh Public health implications of carbapenam resistant enterobacteriaceae Suresh Kumar 13 March (Wednesday /15:50 - 17:30) Session 4 Resistance issues in the community: Nowhere to hide Fluoroquinolone resistance in urinary pathogens Pak Leung Ho ESBL-producing Enterobacteriaceae: alarm calls from Asia Abdul Ghafur Macrolide resistance in mycoplasma species: how do we treat a typical pneumonia? Bin Cao PR Major issues of antimicrobial resistance in children Ritu Banerjee Session 5 Clinical Microbiology Lab: what's new in the future? Challenges in clinical interpretation of antimicrobial susceptibility tests Tse Hsien Koh Molecular detection of resistance genes Franklin Cockerill Rapid diagnosis of sepsis and other severe infections Hui Wang PR Session 6 MDR / XDR Acinetobacter - the rise of a new saga Global emergence of MDR/XDR Acinetobacter spp. Po-Ren Hsueh Genetic mechanisms of MDR/XDR in Acinetobacter spp. Harald Seifert Treatment options for MDR/XDR in Acinetobacter spp. Paul Tambyah

DAY 2 : TREATMENT OF MAJOR INFECTIONS: INTERACTIVE SYMPOSIUM WITH CLINICAL CASES

Session Tentative Topic Speaker 14 March (Thursday / 09:00 - 11:00) Session 7 (Interactive) Treatment updates on tropical diseases Case trops ofical infections (1) Timothy William Cases of tropical infections (2) Visanu Thamlitkitkul Cases of tropical infections (3) Cheng-Hsun Chiu Session 8 (Interactive) Device associated infections Case: Prosthetic joint infection Robin Patel Case: Catheter-associated urinary tract infection Paul Tambyah Case: Catheter related blood stream infection John Turnidge Session 9 (Interactive) Treatment of HIV/AIDS - an update Case: Second-line treatment options Adeeba Kamarulzaman Case: When to start ART after active opportunistic infections Ban Hock Tan Case: TB and HIV Somnuek Sungkanuparph 14 March (Thursday / 15:50 - 17:30) Session 10 (Interactive) Treatment of resistant Gram-positive infections including new antimicrobial agents Case: Hospital Acquired Pneumonia - MRSA pneumonia Petrick Periyasamy Case: Persistent MRSA bacteremia Ian Gould Case: VRE sepsis Robin Patel Session 11 (Interactive) Treatment of resistant Gram-negative infections including new antimicrobial agents Case: Carbapenem-resistant K. pneumoniae sepsis David Livermore Case: Community-acquired ESBL-producing E. coli UTI Abdul Ghafur Case: XDR/PDR Acinetobacter HAP Jien-Wei Liu Session 12 (Interactive) Treatment of fungal infections including new antifungal agents Case: Candida infection Thomas Patterson Case: Invasive apergillosis Kian Meng Chang Case: Cryptococcal infection Methee Chayakulkeeree

DAY 3 : STRATEGIES TO CONTROL AND PREVENT ANTIMICROBIAL RESISTANCE

Session  Tentative Topic Speaker 15 March (Friday / 09:00 - 11:00) Session 13 Antibiotic stewardship: where are we? Antimicrobial stewardship: why, what and how? Stephan Harbarth Asian perspectives: brief introduction of Asian programs Yonghong Xiao PR Doo Ryeon Chung Victor Lim Celia Carlos Li Yang Hsu Session 14 PK/PD PK/PD of colistin Johan Mouton Mathematical modeling Vincent Tam PK/PD in the critically ill John Turnidge Individual dosing of antibiotics in Asians based on PK/PD Sungmin Kiem Session 15 New vaccines on the horizon Staphylococcus aureus vaccine Jean Lee Future of pneumococcal vaccines Raul Isturiz Bionanosome-based vaccines for the protection against superbacterial infection Yoon-Keun Kim 15 March (Friday /15:10 - 16:50) Session 16 Policies and regulations to control resistance Strategies to control AMR in the AP region from the viewpoint of WPRO (or WHO) Hendrik Bekedam How to control antibiotic abuse in the clinical practice? Christopher Lee How to implement policies and regulations to control antibiotic resistance? Shu-Hui Tseng  How to control antibiotic abuse in the animal husbandry? Stephen W Page How to implement policies and regulations to control antibiotic resistance in animal husbandry? Yong Ho Park Session 17 Clinical and economic impact of antimicrobial resistance Clinical impact of antimicrobial resistance Yehuda Carmeli Economic impact of antimicrobial resistance Sara Cosgrove Economic impact of antimicrobial resistance: How to evaluate? Tae-Jin Lee Session 18 Infection control of resistant pathogens Controlling antibiotic resistance in the community Wing Hong Seto Antibiotic stewardship and infection control: Can they contain NDM-1? Anucha Apisarnthanarak Infection control in hospitals: how much do we need active surveillance? Stephan Harbarth